BennuBio Inc
Albuquerque, NM · Founded 2018 · CIK 0001751568 · Medtech · Acquired
Velocyt® multi-stream acoustic flow cytometry system with negative acoustic contrast particle (NACP) immunoassay platform for simultaneous measurement of cell-associated and soluble biomarkers
bennubio.com →- Grants
- $1.5M
- 4 awards
- Sector median: 1
- Raised
- $6.8M
- 3 Form D · Mar 2022
- 54 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 8
- 2 granted · 6 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201820192020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $500,000 | |
| Federal grant | Department of Health and Human Services · Phase II · High-Throughput Spheroid Screening Platform | $499,717 | |
| Private capital raised | Form D · SEC | $5,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · High-Throughput Spheroid Screening Platform | $499,717 | |
| Federal grant | Department of Health and Human Services · Phase I · Demonstration of repeated Positionally Assisted Negative particle Rejection for High-Speed Sorting | $247,435 | |
| Private capital raised | Form D · SEC | $1,324,723 | |
| Federal grant | Department of Health and Human Services · Phase I · Simultaneous analysis of cell-borne and soluble biomarkers by high throughput acoustic flow cytometry | $275,175 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1315 | NEXTGENJANE INC | — | $19M |
| 1316 | Etiometry Inc. | — | $8.2M |
| 1317 | AGIL THERAPEUTICS, INC. | — | — |
| 1318 | BennuBio Inc | — | $6.8M |
| 1319 | Triangle Biotechnology, Inc. | — | — |
| 1320 | VitaThreads LLC | — | $175K |
| 1321 | INFER, INC. | — | $33M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- David BlivinDirector
- Sally CorningDirector
- R. DunlayDirector
- James FreyerExecutive Officer · Promoter
- Steven GravesDirector · Executive Officer · Promoter
- Xin HuangDirector
- Stephen McKernanExecutive Officer
- Waneta TuttleDirector
- Travis WoodsExecutive Officer · Promoter
Patents
- Positionally Assisted Negative particle Rejection (PANR) to sort and enrich target cells of interestgranted
- Optical Cell Constructed By Anodically Bonding A Thin Metal Layer Between Two Optically Clear Glass Windowsgranted
- Systems And Methods Of Serial Enrichment And Dilution (sed) To Sort Target Cellsapplication
- Machined structures in anodically bonded thin metal layer acousto-optical flow cellsapplication
- Angled Flow Cells For Flow Cytometryapplication
- Positionally Assisted Negative Particle Rejection ( Panr) To Sort And Enrich Target Cells Of Interestapplication
- Angled flow cells for flow cytometryapplication
- Machined Structures In Anodically Bonded Thin Metal Layer Acousto- Optical Flow Cellsapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.